TeamDrive
RUS

Leonid Melamed: uncertainty period is the best time to make important tactical and strategical decisions

22 June 2015

June 25, 2015, Vedomosti newspaper office will host a FocusForum Conference in Moscow with a leading participation of Leonid Melamed, the Chairman of Team Drive, member of the Board of Directors of NovaMedica, RMI Partners and Doctor Ryadom. The conference’s goal is to gather experts and share ideas and valuable experience in the time of business challenges. In his video interview to Vedomosti, Leonid explained his vision of the company management tasks in the period of uncertainty. 

Full video is published at Vedomodsti web-site

According to Leonid Melamed, “The time of uncertainty is exactly the time when management should make important decisions both tactical and strategical that are usually postponed in other times or at least realized in a milder way. This is the right time to allocate internal resources aimed to ensure competitive advantages and to cut down the resources spent on the products, processes and areas that do not bring any competitive value in tactical viewpoint. Such periods are the time to reallocate strategic investments in something that will provide competitive value in 3 to 5 years when stability will come in place of uncertainty. Business model also must be changed, if necessary.

In other words, hard times create a welcomed opportunity for drastic changes that were difficult to realize under regular circumstances.”

In hard times, each business unit of the company is a key point. Such circumstances act as a rich soil to grow brilliant ideas and define the company’s future development. And only highly coordinated operation of all business units may lead the company to a success.

The Vedomosti’s FocusForum Conference will take place June 25, 2015, and bring together various experts who will share their ideas and valuable experience and try to identify an action plan for the future. General Managers, Heads of Business Development, HR, Marketing, Advertising and PR will introduce their business cases and strategies during panel discussions, presentations and unofficial personal meetings.

FocusForum web-site


Previous publication Next publication

Media Center

  • 20 April 2018

    Start-up pushes for artificial intelligence to support medical diagnostics

    eleMD, a Russian start-up, is developing a software platform that uses artificial intelligence (AI) for cancer diagnostics and prognostication. Over the past few months the start-up has been focused on fine-tuning the platform’s image recognition functionality for cancer diagnostics, and also on making the solution scalable for medical specialists from across disciplines to be able to analyze heterogeneous medical data. 
     

  • 20 April 2018

    Small biotech companies rule in development of microbiome-targeted therapeutics

    According to leading data and analytics company GlobalData, with smaller biotech companies dominating the pipeline for microbiome-targeted therapeutics, large pharma firms, such as Johnson & Johnson, are eager to collaborate with biotech companies and academic labs to further the development of microbiome-targeted therapeutics in immunology.

  • 19 April 2018

    Can CAR-T and gene therapy cures really sustain biopharma? Not for all, analyst says

    Ever since 2012 when Novartis invested in personalized CAR-T cancer treatments being developed at the University of Pennsylvania, analysts have pondered a difficult question: How can pharma companies profit from curing patients?

  • 18 April 2018

    SID & GP: many Russian pharma companies outdo their foreign counterparts

    According to Vladimir Orlov, Deputy Head of the Educational Center for Good Practices, State Institute of Drugs and Good Practices (SID & GP), a federal budgetary institution, the inspections and checks conducted in major foreign pharmaceutical companies have a great importance for the development of Russian drug manufacturing industry.

Read more